Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.78 |
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284153 | 0.83 | ALDH1A1 (0.78) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL2150045 | 0.83 | ALDH1A1 (0.78) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL5538352 | 0.83 | ALDH1A1 (0.78) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL318395 | 0.83 | ALDH1A1 (0.78) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL5503439 | 0.82 | ALDH1A1 (0.81) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL5544569 | 0.82 | ALDH1A1 (0.81) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL2149364 | 0.82 | ALDH1A1 (0.81) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL8554844 | 0.82 | ALDH1A1 (0.81) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL25320405 | 0.81 | ALDH1A1 (0.84) | ALDH1A1NPSR1TSHRUSP2HPGD | |
| SCHEMBL12124769 | 0.81 | HTR1A (0.82) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8691836-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691836-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2014-04-08 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | ALDH1A1 873/4885NPSR1 30/4885TSHR 68/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | ALDH1A1 873/4885NPSR1 30/4885TSHR 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.